


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method of treating a human patient suffering from an ~~ocular allergy~~ allergic conjunctivitis, comprising:

administering to said patient an ophthalmic composition comprising from about 0.01% to about 0.1% 0.03% to about 0.06% of a macrolide compound having the following formula (I), or a pharmaceutically acceptable salt thereof:



wherein adjacent pairs of R¹ and R², R³ and R⁴, and R⁵ and R⁶ each independently:

a) consist of two adjacent hydrogen atoms, wherein R² is optionally alkyl, or

b) form another bond optionally between carbon atoms binding with the members of pairs:

said pairs;

R^7 is a hydrogen atom, hydroxy, alkyloxy or protected hydroxy, or may form oxo with R^1 ;

R^8 and R^9 each independently show hydrogen atom or hydroxy;

R¹⁰ is a hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl, alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula -CH₂O-;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula N-NR¹¹R¹² or N-OR¹³;

R¹¹ and R¹² each independently are a hydrogen atom, alkyl, aryl or tosyl;

R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³ each independently are a hydrogen atom or alkyl;

R²⁴ is an optionally substituted ring that may contain one or more hetero atom(s); and n is 1 or 2.

Claims 2-3 (Cancelled)

Claim 4 (Previously Presented): A method according to claim 1, wherein said ophthalmic composition comprises about 0.03% of said macrolide compound.

Claim 5 (Previously Presented): A method according to claim 1, wherein said macrolide compound is FK506.

Claim 6 (Previously Presented): A method according to claim 1, wherein said ophthalmic composition is an eye drop.


Claim 7 (Previously Presented): A method according to claim 6, wherein said eye drop further comprises polyvinyl alcohol.

Claim 8 (Previously Presented): A method according to claim 7, wherein said eye drop comprises about 0.03% of said macrolide compound.


Claim 9 (Original): A method according to claim 8, wherein said eye drop is administered from about one to about 4 times per day.

Claim 10 (Cancelled)

Claim 11 (Currently Amended): [[A]] The method according to claim [[10]] 1, wherein said macrolide compound has the following structure:



Claim 12 (Currently Amended): An ophthalmic composition for treatment of ~~ocular~~
~~allergy allergic conjunctivitis~~ comprising from about ~~0.01% to about 0.1%~~ ~~0.03 to about~~
~~0.06%~~ of a macrolide compound having the following formula (I), or a pharmaceutically
acceptable salt thereof:



wherein adjacent pairs of R¹ and R², R³ and R⁴, and R⁵ and R⁶ each independently

a) consist of two adjacent hydrogen atoms, wherein R² is optionally alkyl, or

b) form another bond optionally between carbon atoms binding with the members of

said pairs;

R^7 is a hydrogen atom, hydroxy, alkyloxy or protected hydroxy, or may form oxo with R^1 :

R⁸ and R⁹ each independently are a hydrogen atom or hydroxy;

R¹⁰ is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl,

alkenyl substituted by one or more hydroxy or alkyl substituted by oxo;

Application No. 10/523,842
Reply to Office Action mailed February 6, 2007

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula -CH₂O-;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula N-NR¹¹R¹² or N-OR¹³;

R¹¹ and R¹² each independently are a hydrogen atom, alkyl, aryl or tosyl;

R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³ each independently show hydrogen atom or alkyl;

R²⁴ is an optionally substituted ring that may contain one or more hetero atom(s); and n is 1 or 2.

Claims 13-14 (Cancelled)

Claim 15 (Previously Presented): An ophthalmic composition according to claim 12, comprising about 0.03% of said macrolide compound.

Claim 16 (Previously Presented): An ophthalmic composition according to claim 12, wherein said macrolide compound is FK506.

Claim 17 (Previously Presented): An ophthalmic composition according to claim 12, which is an eye drop.

Claim 18 (Previously Presented): An ophthalmic composition according to claim 17, wherein said eye drop further comprises polyvinyl alcohol.

Claim 19 (Previously Presented): An ophthalmic composition according to claim 18, wherein said eye drop comprises about 0.03% of said macrolide compound.

Claim 20 (Currently Amended): An ophthalmic composition according to claim 19, wherein said eye drop is formulated in a form suitable for administration ~~administered~~ from about one to about 4 times per day.

Claims 21-33 (Canceled)

Claim 34 (Previously Presented): A commercial package comprising the ophthalmic composition of claim 12 and a written matter associated therewith, the written matter stating that the composition can or should be used for allergic conjunctivitis.